IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
40.53%
1 Year Est. Return
+40.53%
AUM
$903M
AUM Growth
-$228M
(-20%)
Holding
109
Top Buys
| 1 | +$28.3M | |
| 2 | +$27.9M | |
| 3 | +$22.6M | |
| 4 |
Baxter International
BAX
|
+$17.1M |
| 5 |
Ascendis Pharma
ASND
|
+$15.6M |
Top Sells
| 1 | +$30.3M | |
| 2 | +$29.6M | |
| 3 | +$29.3M | |
| 4 |
Intuitive Surgical
ISRG
|
+$20.9M |
| 5 |
CVS Health
CVS
|
+$20.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Inspire Medical Systems
INSP
$2.29B
| $10.4M | 1.1% |
65,000
-35,000
|
|
||
27
Tarsus Pharmaceuticals
TARS
$2.79B
| $10.3M | 1.09% |
200,000
-150,000
|
|
||
28
Penumbra
PEN
$9.87B
| $9.36M | 1% |
+35,000
|
|
||
29
Edwards Lifesciences
EW
$44.7B
| $9.06M | 0.96% |
+125,000
|
|
||
30
Revolution Medicines
RVMD
$10.2B
| $8.84M | 0.94% |
250,000
-300,000
|
|
||
31
McKesson
MCK
$99.7B
| $8.08M | 0.86% |
12,000
-23,000
|
|
||
32
MoonLake Immunotherapeutics
MLTX
$605M
| $7.81M | 0.83% |
200,000
|
|
||
33
Teva Pharmaceuticals
TEVA
$21.7B
| $7.68M | 0.82% |
500,000
|
|
||
34
89bio
ETNB
$2.2B
| $7.63M | 0.81% |
1,050,000
+50,000
|
|
||
35
Pfizer
PFE
$141B
| $7.6M | 0.81% |
+300,000
|
|
||
36
Acadia Healthcare
ACHC
$2.16B
| $7.58M | 0.81% |
250,000
-50,000
|
|
||
37
Masimo
MASI
$8.03B
| $7.5M | 0.8% |
+45,000
|
|
||
38
Waters Corp
WAT
$21.4B
| $7.37M | 0.78% |
20,000
-10,000
|
|
||
|
VRNA
39
DELISTED
Verona Pharma
VRNA
| $7.3M | 0.78% |
+115,000
|
|
||
40
DexCom
DXCM
$27.6B
| $6.83M | 0.73% |
100,000
-50,000
|
|
||
41
Regenxbio
RGNX
$658M
| $6.61M | 0.7% |
925,000
+25,000
|
|
||
42
Bristol-Myers Squibb
BMY
$89.2B
| $6.1M | 0.65% |
100,000
-250,000
|
|
||
43
Roivant Sciences
ROIV
$12.4B
| $6.05M | 0.64% |
+600,000
|
|
||
44
Protara Therapeutics
TARA
$197M
| $5.96M | 0.63% |
1,400,000
|
|
||
45
IQVIA
IQV
$37.5B
| $5.29M | 0.56% |
+30,000
|
|
||
46
CRISPR Therapeutics
CRSP
$6.15B
| $5.1M | 0.54% |
+150,000
|
|
||
47
PTC Therapeutics
PTCT
$5.27B
| $5.1M | 0.54% |
+100,000
|
|
||
48
Alkermes
ALKS
$4.92B
| $4.95M | 0.53% |
+150,000
|
|
||
49
Dyne Therapeutics
DYN
$2.44B
| $4.71M | 0.5% |
450,000
+300,000
|
|
||
50
Labcorp
LH
$23.2B
| $4.65M | 0.5% |
+20,000
|
|